Wednesday, July 8, 2026

Patent intelligence · US

US 11084804

Modulators of ATP-binding cassette transporters

granted A61KA61K31/443A61K31/444A61K31/4545
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 991
Patent details — US 11084804
Jurisdiction
US
Status
granted
Grant date
Aug 10, 2021
Expiration
Aug 5, 2041
Claims
1
CPC classes
A61K, A61K31/443, A61K31/444, A61K31/4545
View on Google Patents ↗

Quick answer

US 11084804 (Modulators of ATP-binding cassette transporters) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Aug 10, 2021. Expires Aug 5, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
1
CPC classes
A61K, A61K31/443, A61K31/444, A61K31/4545, A61K31/47, A61K31/4709

More from Vertex Pharmaceuticals Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  2. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Expires Sep 18, 2045

    granted
  3. US 12384790

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  4. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  5. US 12385013

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Aug 7, 2045

    granted
  6. US 12377252

    Implantation devices, system, and methods

    Vertex Pharmaceuticals Incorporated · Expires Jul 31, 2045

    granted
  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Expires Jul 24, 2045

    granted
  8. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 11084804?

US 11084804 (Modulators of ATP-binding cassette transporters) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Aug 10, 2021. Expires Aug 5, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11084804?

Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.

When does US 11084804 expire?

Our index shows an expiration date of Aug 5, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.